Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia

Phase III, randomised, double-blind, placebo-controlled study of the β3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder

(2014) Osamu Yamaguchi et al.   BJU INTERNATIONAL

Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies

(2013) V. W. Nitti et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicentre Study to Assess the Efficacy and Safety of the β3 Adrenoceptor Agonist, Mirabegron, in Patients With Symptoms of Overactive Bladder

(2013) Sender Herschorn et al.   UROLOGY

Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European–Australian Phase 3 Trial

(2012) Vik Khullar et al.   EUROPEAN UROLOGY

Results of a Randomized Phase III Trial of Mirabegron in Patients with Overactive Bladder

(2012) Victor W. Nitti et al.   JOURNAL OF UROLOGY

Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction

(2011) Debra E. Irwin et al.   BJU INTERNATIONAL

The placebo effect in overactive bladder syndrome

(2011) Altaf Mangera et al.   Nature Reviews Urology

Patient-reported reasons for discontinuing overactive bladder medication

(2009) Joshua S. Benner et al.   BJU INTERNATIONAL

A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder

(2009) Soyon Lee et al.   BMC Medical Research Methodology

Clinical guidelines for overactive bladder

(2009) Osamu Yamaguchi et al.   INTERNATIONAL JOURNAL OF UROLOGY

Effects of CL316,243, a β3-adrenoceptor agonist, and intravesical prostaglandin E2 on the primary bladder afferent activity of the rat

(2009) Naoki Aizawa et al.   NEUROUROLOGY AND URODYNAMICS

Persistence of antimuscarinic drug use

(2008) Søren Brostrøm et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

The Effects of Antimuscarinic Treatments in Overactive Bladder: An Update of a Systematic Review and Meta-Analysis

(2008) Christopher R. Chapple et al.   EUROPEAN UROLOGY